Evidence map›Paper›PMID 36656385›Full record

Observational studyArchives of dermatological research2023

Prevalence of adverse events varies with the different oral isotretinoin brands in acne treatment: a retrospective observational study.

Boutros Soutou, Joelle Sleiman, Roland Tomb, Elio Kechichian, Josiane Helou

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Archives of dermatological research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Boutros Soutou *Dermatology Department, Faculté de Médecine, Université Saint-Joseph, Beirut, Lebanon. boutros.soutou@usj.edu.lb.ORCID http://orcid.org/0000-0002-3906-7021
Joelle Sleiman *Dermatology Department, Faculté de Médecine, Université Saint-Joseph, Beirut, Lebanon.
Roland TombDermatology Department, Faculté de Médecine, Université Saint-Joseph, Beirut, Lebanon.
Elio KechichianDermatology Department, Faculté de Médecine, Université Saint-Joseph, Beirut, Lebanon.
Josiane HelouDermatology Department, Faculté de Médecine, Université Saint-Joseph, Beirut, Lebanon.
Saint Joseph University · LB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oral isotretinoin remains the most effective treatment for acne. The aim of this retrospective single-center cohort study was to estimate the prevalence of adverse events with the different oral isotretinoin brands used in acne treatment. The population consisted of all patients who consulted for acne between January 2015 and January 2020. The inclusion criterion was the initiation of treatment with oral isotretinoin. The exclusion criteria were the use of two or more brands during the same course of treatment and previous treatment with oral isotretinoin. Statistical analysis was carried out using Chi-square and Mann-Whitney tests. We analyzed 468 patients of whom 68.6% were female. The median age was 21 years. The median weight was 65 kg. The treatment was Roaccutane

Indexed as

Acne VulgarisDermatologic AgentsHypercholesterolemiaHypertriglyceridemiaAdministration, OralAdultCohort StudiesFemaleHumansIsotretinoinMalePrevalenceRetrospective StudiesYoung AdultDermatologic AgentsIsotretinoinAcneAdverse eventsEpidemiologyOral isotretinoin

Identifiers

PMID36656385
OpenAlexW4317477194

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.